Matthias M Engelen

MD PhD - Cardiologist in training - Former athlete and sports enthousiast

[Thrombosis Update @ThrombUpdate]

FXI inhibitors promise to prevent thrombosis while maintaining hemostasis.
In this recent review, the authors provided insights into FXI inhibitors and future perspectives.
@VerhammePeter @MatthiasEngelen @ELShematology
#ThrJournal
Read more here: https://t.co/OHqZy5hKlj

[Matthias M Engelen @MatthiasEngelen]

Everything you need to know about atrial myopathy, a comprehensive review by the amazing @michieltubeeckx

[Basic Research in Cardiology @BasicResCardiol]

Atrial myopathy and fibrillation.
https://t.co/bEVwAtCUaN

[Sebastiaan Dhont @S_Dhont]

📰👀 Exercise Pulmonary Hypertension by the mPAP/CO slope in Primary Mitral Regurgitation.

Read our last paper in @ESC_Journals: https://t.co/Vk9t2esc1S

🧵✅

🇧🇪@Ph_Bertrand @VerwerftJan @HerbotsLieven @sarahhoed @YouriBekhuis @maartenfalter @JasaityteRuta @pietvandervoort

[Philippe B. Bertrand @Ph_Bertrand]

👇🏼 Very proud of these novel data, potential clinical impact +++

Great collaboration between @ZOLziekenhuis & @JessaZiekenhuis, @GLW_UHasselt 🇧🇪

Importance of exercise PHT by mPAP/CO slope in risk-stratification of primary MR.

@VerwerftJan @S_Dhont

[Elisabet Van Loon @ElisabetVl]

📢Urinary chemokines CXCL9&10 integrated with clinical parameters for noninvasive monitoring of rejection could significantly reduce the number of biopsies🔬. This study paves the way🛣️ for implementation in clinical practice 🏥

[Wouter L’Hoyes @LHoyesWouter]

🫀 Predictors of and outcome in arrhytmic mitral valve prolapse

👥 169 patients with MVP who underwent CMR

👉 LGE and MAD as only predictors of AMVP

💡 Low event rates ↔️ ICD implantation reasonable in 69.7% patients according EHRA consensus
#CMR #Cardiology @AmericanHeartJ

[Matthias M Engelen @MatthiasEngelen]

Make sure to keep an eye open for the PRIORITY results in the coming years! After reading the protocol paper of this multicenter prospective RCT in patients along the HFpEF continuum (stage A-C), you will understand what all the buzz is about! 🐝 🫀 👏🏻

[Youri Bekhuis @YouriBekhuis]

🔊 The first PRIORITY publication is now available in @FrontCVMedicine!

In this paper, we describe the rationale and design of our multicenter prospective RCT in patients along the HFpEF continuum (stage A-C).

Link: https://t.co/M0WEqd0CKR
Short tweetorial: 👇
1/n

[Matthias M Engelen @MatthiasEngelen]

@KarelDavid_ @KU_Leuven @FWOVlaanderen @EvenepoelPieter @MolendoKUL @GeertLab @BammensBert @MaartenAlbersen Amazing work Karel; an example for so many young scientists! Wish I was there!

[Matthias M Engelen @MatthiasEngelen]

Such an honour to be awarded with a @RPTHjournal Early Career Editor’s Awards at #ISTH2023 by the amazing @MaryCushmanMD, together with mentors Thomas Vanassche and @VerhammePeter for our paper on modulation of thromboinflammation in #COVID19 👉🏻 https://t.co/U0oQWn9j6M

[RPTH @RPTHjournal]

Celebrating the @RPTHjournal Early Career Editor’s Award Winners at #ISTH2023.

@MatthiasEngelen @MaryCushmanMD @isth

[Matthias M Engelen @MatthiasEngelen]

Delighted to discuss these important steps for patients with acquired hemophilia A (AHA) together with all colleagues here at #ISTH2023 🇨🇦! Details of our talk on emicizumab in AHA now available online 👉🏻 https://t.co/pUAgCY0y4r

[Haemophilia Journal @haemophilia_jnl]

In a Belgian 🇧🇪 case series, emicizumab was successfully used for prevention of further bleeding in 7 patients w/ acquired #haemophilia A. Results of this study will be presented by @MatthiasEngelen at the #ISTH2023 congress 👨‍🏫 👉https://t.co/BHThVzz49Y #FreeToRead ⏳

[Matthias M Engelen @MatthiasEngelen]

Very honored with this RPTH Editor's Award! Many thanks to all colleagues and participating centers for their efforts in challenging times! @t_vanassche @VerhammePeter @UZLeuven @gzaziekenhuizen @ZOLziekenhuis

[RPTH @RPTHjournal]

🎉We're pleased to announce 3 early career researchers as the latest recipients of our Editor's Awards: @MatthiasEngelen, @Tessa_Noorder and Jie Sun. Learn more and read their award-winning work here: https://t.co/16VAAQAwFk

[MedEd On The Go @MedEdOTG]

Watch @MatthiasEngelen MD present #ISTH2022 news on DAWn-Antico Study on modulation of host thromboinflammatory response in hospitalized COVID patients. Spend 7 info-packed minutes: https://t.co/BZmGc6qGfD

[Peter Verhamme @VerhammePeter]

Modulation of Host Thromboinflammatory Response in Hospitalized Patients with COVID-19: The DAWn-Antico Study. An absolute highlight of ISTH 2022! ⁦@MatthiasEngelen⁩ https://t.co/sRYE6VdB2R

[Yazan Abou-Ismail, MD - د. يزن أبواسماعيل @DoctorYazanA]

In this multicenter RCT, upstream + downstream modulation of thromboinflammation in hospitalized mod/severe COVID19 patients using cocktail of high-dose aprotinin + LMWH +/- anakinra was safe but did not improve clinical or biochemical outcomes vs SOC. #ISTH2022 @MatthiasEngelen

[Center for Molecular and Vascular Biology @CMVB_KULeuven]

CMVB tomorrow at #ISTH2022 meeting !! Presentations from @MatthiasEngelen on COVID and the DAWn_Antico study & @kmartinod on recommendations for NETs measurements in SSC session. Also posters from @ValerieSpalart and again @MatthiasEngelen

[RPTH @RPTHjournal]

After implementing a weight- & illness severity-adjusted thromboprophylaxis regimen, this single-center eliminated symptomatic #VTE, ⬇️ incidental VTE, & lowered risk of bleeding compared to standard prophylaxis. https://t.co/R0ttG6CplF @MatthiasEngelen @CVandenbriele @kmartinod

[Peter Verhamme @VerhammePeter]

Belgische arts Laurens Liesenborghs onderzoekt apenpokken in Congo: "Variant in Westen wellicht milder"
https://t.co/i9GdQY3VTZ

[Matthias M Engelen @MatthiasEngelen]

This well-performed RCT compares therapeutically dosed (intervention) with weight and severity adjusted (control) #thromboprophylaxis in #COVID19; showing good prognosis in both groups #VTE #thrombosis #DIC #majorbleeding #death

[Marc Blondon @MarcBlondon]

Our Swiss COVID-HEP trial showing a good clinical prognosis, independently of the anticoagulation dose https://t.co/56poR5w2M8 @Hopitaux_unige @RPTHjournal

[Matthias M Engelen @MatthiasEngelen]

Early in the pandemic, our center switched to a weight- and severity adjusted intensified thromboprophylactic protocol in #COVID19. In @RPTHjournal we discuss the promising results and the randomized data available to date @VerhammePeter @UZLeuven @CMVB_KULeuven @Cardio_KULeuven

[RPTH @RPTHjournal]

What anticoagulant dose is optimal in hospital patients with #COVID19? Researchers investigated the efficacy of weight-adjusted dosing in 412 patients. #VTE and #bleeding were primary outcomes… https://t.co/R0ttG6CplF @MatthiasEngelen @CVandenbriele @kmartinod

[Matthias M Engelen @MatthiasEngelen]

Brilliant event! How amazing to catch up with colleagues in person again. Blown away by all the exciting research our department has to offer! Big thanks to @Cardio_KULeuven!

[Department of Cardiovascular Sciences - KU Leuven @Cardio_KULeuven]

Department Event yesterday. PhDs and postdocs presented their research by posters. Matthias Engelen won 'best clinical poster' for his research into blood clots in Covid-19. Mohamad Youness won 'best basic poster' for his research on cardiomyopathy #postdoc #departmentevent #PhD